BIIB Q3 2024 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B-2.5% YoY

Gross Profit

$1.8B74.1% margin

Operating Income

$577M23.4% margin

Net Income

$389M15.8% margin

EPS (Diluted)

$2.66

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

$936M

Free Cash Flow

$806M

Stock-Based Comp.

$73M

Balance Sheet

Total Assets

$28.3B

Total Liabilities

$12.0B

Stockholders' Equity

$16.4B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.5B	-2.5%
Gross Profit	$1.8B	$1.9B	-2.3%
Operating Income	$577M	$321M	+79.9%
Net Income	$389M	-$68M	+670.5%

Revenue Segments

MS Product Revenues

$1.1B43%

TYSABRI product

$406M16%

Fumarate

$391M16%

SPINRAZA

$381M15%

Interferon

$238M10%

Geographic Segments

Non-US

$956M54%

UNITED STATES

$813M46%